BACKGROUND: Cannabis use is associated with psychosis and a range of subclinical psychiatric symptoms. The strength of this association depends on dosage and age at first use. The current study investigates whether level of cannabis exposure and starting age are associated with specific profiles of subclinical symptoms. METHOD: We collected cross-sectional data from a young adult population sample by administering an online version of the Community Assessment of Psychic Experiences (CAPE). Cannabis exposure was quantified as the amount of Euros spent on cannabis per week and the age of initial cannabis use. The primary outcome measure was the odds ratio (OR) to belong to the highest 10% of scores on the total CAPE and the positive-, negative- and depressive symptom dimensions. RESULTS: In 17 698 adolescents (mean age 21.6, s.d.=4.2 years), cannabis use at age 12 years or younger was strongly associated with a top 10% score on psychotic experiences [OR 3.1, 95% confidence interval (CI) 2.1-4.3] and to a lesser degree with negative symptoms (OR 1.7, 95% CI 1.1-2.5). The OR of heavy users (>€25/week) for negative symptoms was 3.4 (95% CI 2.9-4.1), for psychotic experiences 3.0 (95% CI 2.4-3.6), and for depressive symptoms 2.8 (95% CI 2.3-3.3). CONCLUSIONS: Early start of cannabis use is strongly associated with subclinical psychotic symptoms and to a lesser degree with negative symptoms, while smoking high amounts of cannabis is associated with increased levels of all three symptom dimensions: psychotic, negative and depressive. These results support the hypothesis that the impact of cannabis use is age specific.
BACKGROUND: Cannabis use is associated with psychosis and a range of subclinical psychiatric symptoms. The strength of this association depends on dosage and age at first use. The current study investigates whether level of cannabis exposure and starting age are associated with specific profiles of subclinical symptoms. METHOD: We collected cross-sectional data from a young adult population sample by administering an online version of the Community Assessment of Psychic Experiences (CAPE). Cannabis exposure was quantified as the amount of Euros spent on cannabis per week and the age of initial cannabis use. The primary outcome measure was the odds ratio (OR) to belong to the highest 10% of scores on the total CAPE and the positive-, negative- and depressive symptom dimensions. RESULTS: In 17 698 adolescents (mean age 21.6, s.d.=4.2 years), cannabis use at age 12 years or younger was strongly associated with a top 10% score on psychotic experiences [OR 3.1, 95% confidence interval (CI) 2.1-4.3] and to a lesser degree with negative symptoms (OR 1.7, 95% CI 1.1-2.5). The OR of heavy users (>€25/week) for negative symptoms was 3.4 (95% CI 2.9-4.1), for psychotic experiences 3.0 (95% CI 2.4-3.6), and for depressive symptoms 2.8 (95% CI 2.3-3.3). CONCLUSIONS: Early start of cannabis use is strongly associated with subclinical psychotic symptoms and to a lesser degree with negative symptoms, while smoking high amounts of cannabis is associated with increased levels of all three symptom dimensions: psychotic, negative and depressive. These results support the hypothesis that the impact of cannabis use is age specific.
Authors: Evan A Winiger; Spencer B Huggett; Alexander S Hatoum; Michael C Stallings; John K Hewitt Journal: Drug Alcohol Depend Date: 2019-08-30 Impact factor: 4.492
Authors: A Vreeker; M P M Boks; L Abramovic; S Verkooijen; A H van Bergen; M H J Hillegers; A T Spijker; E Hoencamp; E J Regeer; R F Riemersma-Van der Lek; A W M M Stevens; P F J Schulte; R Vonk; R Hoekstra; N J M van Beveren; R W Kupka; R M Brouwer; C E Bearden; J H MacCabe; R A Ophoff Journal: Psychol Med Date: 2015-12-01 Impact factor: 7.723
Authors: Jibran Y Khokhar; Lucas L Dwiel; Angela M Henricks; Wilder T Doucette; Alan I Green Journal: Schizophr Res Date: 2017-04-14 Impact factor: 4.939
Authors: Sukanta Saha; James G Scott; Daniel Varghese; Louisa Degenhardt; Tim Slade; John J McGrath Journal: BMC Psychiatry Date: 2011-12-28 Impact factor: 3.630
Authors: Camelia C Minică; Karin J H Verweij; Peter J van der Most; Hamdi Mbarek; Manon Bernard; Kristel R van Eijk; Penelope A Lind; Meng Zhen Liu; Dominique F Maciejewski; Teemu Palviainen; Cristina Sánchez-Mora; Richard Sherva; Michelle Taylor; Raymond K Walters; Abdel Abdellaoui; Timothy B Bigdeli; Susan J T Branje; Sandra A Brown; Miguel Casas; Robin P Corley; George Davey-Smith; Gareth E Davies; Erik A Ehli; Lindsay Farrer; Iryna O Fedko; Iris Garcia-Martínez; Scott D Gordon; Catharina A Hartman; Andrew C Heath; Ian B Hickie; Matthew Hickman; Christian J Hopfer; Jouke Jan Hottenga; René S Kahn; Jaakko Kaprio; Tellervo Korhonen; Henry R Kranzler; Ken Krauter; Pol A C van Lier; Pamela A F Madden; Sarah E Medland; Michael C Neale; Wim H J Meeus; Grant W Montgomery; Ilja M Nolte; Albertine J Oldehinkel; Zdenka Pausova; Josep A Ramos-Quiroga; Vanesa Richarte; Richard J Rose; Jean Shin; Michael C Stallings; Tamara L Wall; Jennifer J Ware; Margaret J Wright; Hongyu Zhao; Hans M Koot; Tomas Paus; John K Hewitt; Marta Ribasés; Anu Loukola; Marco P Boks; Harold Snieder; Marcus R Munafò; Joel Gelernter; Dorret I Boomsma; Nicholas G Martin; Nathan A Gillespie; Jacqueline M Vink; Eske M Derks Journal: Addiction Date: 2018-08-19 Impact factor: 6.526
Authors: Marta Di Forti; Hannah Sallis; Fabio Allegri; Antonella Trotta; Laura Ferraro; Simona A Stilo; Arianna Marconi; Caterina La Cascia; Tiago Reis Marques; Carmine Pariante; Paola Dazzan; Valeria Mondelli; Alessandra Paparelli; Anna Kolliakou; Diana Prata; Fiona Gaughran; Anthony S David; Craig Morgan; Daniel Stahl; Mizanur Khondoker; James H MacCabe; Robin M Murray Journal: Schizophr Bull Date: 2013-12-17 Impact factor: 9.306